FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

heck this box if no longer subject to
ection 16. Form 4 or Form 5
oligations may continue. See
ctruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     DUGAN RICHARD W						2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]									elationship eck all appli X Directo	cable)	g Per	son(s) to Iss		
(Last)	•	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/08/2023										(give title		Other (s below)		
298 BEACON CIRCLE						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BOALSBURG PA 16827														X Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - No	n-Deriv	vative	Se	curities	s Ac	quired,	Dis	posed o	of, or	Ben	eficial	ly Owned	t				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da						Executio			Transaction Dispos		Dispose	rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar			Benefici Owned	es ially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)		Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 06/08/				/2023				A		17,307	7 <sup>(1)</sup> A \$		\$0.00	97,700			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	n Date,	4. Transac Code (li 8)		n of		6. Date Ex Expiration (Month/Da	Date	Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisabl		expiration Date	Title	O N	Amount or Number of Shares						
Stock Option (Right to	\$6.5	06/08/2023			A		33,960		(2)	0	6/07/2033	Comm		33,960	\$0.00	33,960	)	D		

## **Explanation of Responses:**

- 1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
- 2. This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting

## Remarks:

/s/ Richard W. Dugan

\*\* Signature of Reporting Person

06/09/2023 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.